zuma-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; kte-c19) in patients with nhl
Published 7 years ago • 1.6K plays • Length 2:24Download video MP4
Download video MP3
Similar videos
-
2:17
zuma-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk lbcl
-
1:15
primary overall survival analysis of the zuma-7 trial
-
2:48
zuma-1: safety and efficacy of axicabtagene in refractory non-hodgkin lymphoma patients
-
1:34
zuma-1 update: safety data of axi-cel in patients with r/r dlbcl
-
2:59
axi-cel in older patients: data from zuma-1 and clinical use
-
0:54
insights into the zuma-23 trial: axi-cel in frontline high-risk lbcl
-
9:16
protrombin time (pt) & activated partial tromboplastin time (aptt)|coagulation analyzer|wila djami
-
43:53
chapter 1 basic hematology ( introduction )
-
22:38
introduction to haematology part 1
-
3:31
zuma-1 trial observations
-
2:32
zuma-1 update: durable survival in r/r dlbcl patients treated with axi-cel
-
3:32
zuma-1: updated data and future prospects
-
2:00
long-term follow-up results of the zuma-1 trial of anti-cd19 car t-cells for non-hodgkin lymphoma
-
2:19
zuma-3: identifying the optimal dose of axi-cel in r/r all
-
6:37
zuma-7: axi-cel in r/r large b-cell lymphoma
-
1:44
comparison of zuma-1 and scholar-1 outcomes
-
2:38
zuma-1 & scholar-1: comparison of outcomes in refractory dlbcl
-
2:09
zuma series update: zuma-1 and zuma-2
-
3:10
zuma-9: expanded access protocol and oos axicabtagene ciloleucel in r/r dlbcl
-
2:26
zuma-5: high orr and cr for r/r inhl with axi-cel
-
0:54
zuma-3 end of phase i results: axi-cel for r/r all
-
3:05
zuma-1, juliet and transcend trials: changing the treatment landscape for r/r nhl